ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).
Richard A. Larson
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Dong-Wook Kim
Consultant or Advisory Role - Bristol-Myers Squibb; Il-Yang ; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
Saengsuree Jootar
No relevant relationships to disclose
Ricardo Pasquini
No relevant relationships to disclose
Richard E. Clark
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Clarisse Lobo
Honoraria - Novartis
Stuart L. Goldberg
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Hirohiko Shibayama
Honoraria - Novartis
Research Funding - Novartis
Andreas Hochhaus
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Giuseppe Saglio
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Hagop M. Kantarjian
No relevant relationships to disclose
Charisse Kemp
Employment or Leadership Position - Novartis
Weiping Deng
Employment or Leadership Position - Novartis
Hans D. Menssen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis